MX306302B - Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli - Google Patents

Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli

Info

Publication number
MX306302B
MX306302B MX2007010043A MX2007010043A MX306302B MX 306302 B MX306302 B MX 306302B MX 2007010043 A MX2007010043 A MX 2007010043A MX 2007010043 A MX2007010043 A MX 2007010043A MX 306302 B MX306302 B MX 306302B
Authority
MX
Mexico
Prior art keywords
meningitis
sepsis
proteins
nucleic acids
escherichia coli
Prior art date
Application number
MX2007010043A
Other languages
English (en)
Spanish (es)
Other versions
MX2007010043A (en
Inventor
Laura Serino
Vega Masignani
Herve Tettelin
Mariagrazia Pizza
Francesco Berlanda Scorza
Original Assignee
Inst Genomic Research
Novartis Vaccines & Diagnostic
Francesco Berlanda Scorza
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Genomic Research, Novartis Vaccines & Diagnostic, Francesco Berlanda Scorza filed Critical Inst Genomic Research
Publication of MX2007010043A publication Critical patent/MX2007010043A/es
Publication of MX306302B publication Critical patent/MX306302B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2007010043A 2005-02-18 2007-08-17 Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli MX306302B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65463205P 2005-02-18 2005-02-18
US71272005P 2005-08-29 2005-08-29

Publications (2)

Publication Number Publication Date
MX2007010043A MX2007010043A (en) 2008-08-29
MX306302B true MX306302B (en) 2012-12-19

Family

ID=36917149

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007010043A MX306302B (en) 2005-02-18 2007-08-17 Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli

Country Status (18)

Country Link
US (4) US8758764B2 (OSRAM)
EP (2) EP2351772B1 (OSRAM)
JP (2) JP2008529558A (OSRAM)
AU (1) AU2006214064B2 (OSRAM)
CA (1) CA2601924A1 (OSRAM)
CY (2) CY1117732T1 (OSRAM)
DK (2) DK1858920T3 (OSRAM)
ES (2) ES2595363T3 (OSRAM)
HU (2) HUE030881T2 (OSRAM)
IL (2) IL185359A0 (OSRAM)
LT (1) LT2351772T (OSRAM)
MX (1) MX306302B (OSRAM)
NZ (3) NZ597685A (OSRAM)
PL (2) PL1858920T3 (OSRAM)
PT (1) PT2351772T (OSRAM)
SG (1) SG160329A1 (OSRAM)
SI (2) SI2351772T1 (OSRAM)
WO (1) WO2006089264A2 (OSRAM)

Families Citing this family (189)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1154790E (pt) * 1999-02-26 2005-03-31 Chiron Srl Reforco da actividade bactericida de antigenios contra a neisseria com oligonucleotidos contendo motivos cg
AU1412702A (en) * 2000-10-27 2002-05-06 Chiron Spa Nucleic acids and proteins from streptococcus groups a and b
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
SI2351772T1 (sl) 2005-02-18 2016-11-30 Glaxosmithkline Biologicals Sa Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso
EP2201961B1 (en) 2005-06-27 2018-01-24 GlaxoSmithKline Biologicals S.A. Immunogenic composition
JP2010500399A (ja) 2006-08-16 2010-01-07 ノバルティス アーゲー 尿路病原性大腸菌由来の免疫原
ITMI20081249A1 (it) 2008-07-09 2010-01-09 Novartis Vaccines & Diagnostic Immunogeni di escherichia coli con solubilità migliorata.
JP5332237B2 (ja) * 2008-03-06 2013-11-06 味の素株式会社 Ｌ−システイン生産菌及びｌ−システインの製造法
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
NZ591768A (en) 2008-09-18 2012-11-30 Novartis Ag Vaccine adjuvant combinations
US9669060B2 (en) * 2009-04-23 2017-06-06 Cornell University Compositions for preventing and treating uterine disease
US9119802B2 (en) * 2009-05-06 2015-09-01 Cornell University E. coli LpfA antigen for prevention and treatment of infectious diseases
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
ES2596653T3 (es) 2009-06-16 2017-01-11 Glaxosmithkline Biologicals Sa Ensayos bactericidas de opsonización y dependientes de anticuerpo mediado por el complemento de alto rendimiento
US10988511B2 (en) * 2009-07-07 2021-04-27 Glaxosmithkline Biologicals Sa Conserved Escherichia bacterial IG-like domain (group 1) protein (ORF405) immunogens
SG178035A1 (en) 2009-07-16 2012-03-29 Novartis Ag Detoxified escherichia coli immunogens
EP2277989A1 (en) 2009-07-24 2011-01-26 Technische Universiteit Delft Fermentative glycerol-free ethanol production
AU2010288239B2 (en) * 2009-08-27 2014-01-16 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
SG178954A1 (en) 2009-09-02 2012-04-27 Novartis Ag Immunogenic compositions including tlr activity modulators
ES2387719T3 (es) * 2009-09-10 2012-09-28 Freie Universität Berlin Identificación y caracterización de una nueva adhesina fimbrial de E. coli patógena aviar (APEC)
EP2482836B1 (en) * 2009-10-02 2016-04-13 Oslo Universitetssykehus HF Antibacterial polypeptides and use thereof
US8741591B2 (en) 2009-10-09 2014-06-03 The Research Foundation For The State University Of New York pH-insensitive glucose indicator protein
KR101735675B1 (ko) 2009-12-11 2017-05-15 오티포니 세라피틱스 리미티드 이미다졸리딘디온 유도체
ES2707778T3 (es) * 2009-12-30 2019-04-05 Glaxosmithkline Biologicals Sa Inmunógenos polisacáridos conjugados con proteínas portadoras de E. coli
ES2646669T3 (es) 2010-07-06 2017-12-14 Glaxosmithkline Biologicals Sa Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
HUE026646T2 (en) 2010-07-06 2016-07-28 Glaxosmithkline Biologicals Sa Preferred liposomes containing lipids of PKA value for delivery of RNA
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
HRP20161352T1 (hr) 2010-07-06 2016-12-02 Glaxosmithkline Biologicals Sa Čestice nalik na virione za unos samoreplicirajućih molekula rna
ES2586580T3 (es) 2010-07-06 2016-10-17 Glaxosmithkline Biologicals Sa Inmunización de mamíferos grandes con dosis bajas de ARN
DK4226941T3 (da) 2010-08-31 2024-12-02 Glaxosmithkline Biologicals Sa Pegylerede liposomer til levering af immunogen-kodende rna
CN103384515B (zh) 2010-08-31 2017-02-15 诺华有限公司 适用于脂质体递送编码蛋白质的rna的脂质
US20120177681A1 (en) 2010-09-01 2012-07-12 Manmohan Singh Formulation of immunopotentiators
US9259462B2 (en) 2010-09-10 2016-02-16 Glaxosmithkline Biologicals Sa Developments in meningococcal outer membrane vesicles
KR102266691B1 (ko) 2010-10-11 2021-06-23 노파르티스 아게 항원 전달 플랫폼
US9618508B2 (en) 2010-12-14 2017-04-11 Glaxosmithkline Biologicals Sa Flow cytometry analysis of materials adsorbed to metal salts
WO2012103421A1 (en) 2011-01-27 2012-08-02 Novartis Ag Adjuvant nanoemulsions with crystallisation inhibitors
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10086018B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11357722B2 (en) 2011-02-04 2022-06-14 Seed Health, Inc. Method and system for preventing sore throat in humans
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US10583033B2 (en) 2011-02-04 2020-03-10 Katherine Rose Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US10085938B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for preventing sore throat in humans
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11191665B2 (en) 2011-02-04 2021-12-07 Joseph E. Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US10010568B2 (en) 2011-02-04 2018-07-03 Katherine Rose Kovarik Method and system for reducing the likelihood of a spirochetes infection in a human being
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US9987224B2 (en) 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US10940169B2 (en) 2015-11-30 2021-03-09 Joseph E. Kovarik Method for reducing the likelihood of developing cancer in an individual human being
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US10835560B2 (en) 2013-12-20 2020-11-17 Joseph E. Kovarik Reducing the likelihood of skin cancer in an individual human being
US10111913B2 (en) 2011-02-04 2018-10-30 Joseph E. Kovarik Method of reducing the likelihood of skin cancer in an individual human being
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US10687975B2 (en) 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
TR201811280T4 (tr) 2011-03-02 2018-08-27 Glaxosmithkline Biologicals Sa Düşük antijen ve/ veya adjuvan dozları olan karma aşılar.
ES2785108T3 (es) 2011-03-24 2020-10-05 Glaxosmithkline Biologicals Sa Nanoemulsiones adyuvantes con fosfolípidos
US11896636B2 (en) 2011-07-06 2024-02-13 Glaxosmithkline Biologicals Sa Immunogenic combination compositions and uses thereof
CN103764121A (zh) 2011-07-06 2014-04-30 诺华股份有限公司 用于递送rna分子的具有有用n:p比的脂质体
US20140255472A1 (en) 2011-08-31 2014-09-11 Andrew Geall Pegylated liposomes for delivery of immunogen-encoding rna
EP2755994A2 (en) 2011-09-14 2014-07-23 Novartis AG Escherichia coli vaccine combination
KR101359844B1 (ko) * 2012-01-06 2014-02-25 씨제이제일제당 (주) 퀴놀린산을 생산하는 재조합 미생물 및 이를 이용한 퀴놀린산의 생산 방법
US9765369B2 (en) * 2012-01-18 2017-09-19 Mitsui Chemicals, Inc. Method for producing 1,5-pentamethylenediamine, mutant lysine decarboxylase, method for producing 1,5-pentamethylene diisocyanate and method for producing polyisocyanate composition
SI2822947T1 (sl) 2012-03-07 2016-10-28 Glaxosmithkline Biologicals S.A. Argininske soli TLR7 agonista
EP2822586A1 (en) 2012-03-07 2015-01-14 Novartis AG Adjuvanted formulations of streptococcus pneumoniae antigens
EP2822581A2 (en) 2012-03-08 2015-01-14 Novartis AG Adjuvanted formulations of dtp booster vaccines
WO2014014207A1 (en) * 2012-07-20 2014-01-23 University-Industry Cooperation Group Of Kyung Hee University Antibody for epitope tagging, hybridoma cell line and uses thereof
EP2897635A1 (en) 2012-09-18 2015-07-29 Novartis AG Outer membrane vesicles
WO2014060555A1 (en) * 2012-10-17 2014-04-24 Enterome Gene signatures of inflammatory disorders that relate to the liver
WO2014078270A1 (en) * 2012-11-13 2014-05-22 The General Hospital Corporation In vitro assays for detecting salmonella enterica serotype typhi
WO2014102694A1 (en) 2012-12-24 2014-07-03 Novartis Ag Novel mucinase for use in therapy or prophylaxis
EA201891018A1 (ru) 2013-03-08 2018-09-28 Новартис Аг Липиды и липидные композиции для доставки активных агентов
US9885033B2 (en) 2013-03-15 2018-02-06 The General Hospital Corporation Increasing specificity for RNA-guided genome editing
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
KR101525663B1 (ko) 2013-05-10 2015-06-04 씨제이제일제당 (주) 신규 ｏ-포스포세린 배출 단백질 및 이를 이용한 ｏ-포스포세린의 생산방법
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US10011850B2 (en) 2013-06-21 2018-07-03 The General Hospital Corporation Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
US10195257B2 (en) * 2013-07-28 2019-02-05 Qantu Therapeutics, Inc. Vaccine formulations comprising quillaja desacylsaponins and beta amyloid peptides or tau protein to induce a Th2 immune response
KR20150018227A (ko) * 2013-08-09 2015-02-23 삼성전자주식회사 외인성 푸마라아제 유전자를 포함하는 코리네박테리움 및 이를 이용한 c4 디카르복실산의 생산 방법
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
CA2930015A1 (en) 2013-11-07 2015-05-14 Editas Medicine, Inc. Crispr-related methods and compositions with governing grnas
EP3083579B1 (en) 2013-12-19 2022-01-26 Novartis AG Lipids and lipid compositions for the delivery of active agents
EP3083556B1 (en) 2013-12-19 2019-12-25 Novartis AG Lipids and lipid compositions for the delivery of active agents
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US12318377B2 (en) 2013-12-20 2025-06-03 Seed Health, Inc. Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US11672835B2 (en) 2013-12-20 2023-06-13 Seed Health, Inc. Method for treating individuals having cancer and who are receiving cancer immunotherapy
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11529379B2 (en) 2013-12-20 2022-12-20 Seed Health, Inc. Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11213552B2 (en) 2015-11-30 2022-01-04 Joseph E. Kovarik Method for treating an individual suffering from a chronic infectious disease and cancer
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11642382B2 (en) 2013-12-20 2023-05-09 Seed Health, Inc. Method for treating an individual suffering from bladder cancer
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11026982B2 (en) 2015-11-30 2021-06-08 Joseph E. Kovarik Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
EP3536168A3 (en) 2014-03-06 2019-10-16 The Research Institute at Nationwide Children's Hospital Probiotic formulations and methods for use
US10624934B2 (en) 2014-03-06 2020-04-21 Research Institute At Nationwide Children's Hospital Prebiotic formulations
CL2014001126A1 (es) * 2014-04-29 2014-08-29 Univ Chile Composición farmacéutica útil como vacuna contra bacterias escherichia coli productoras de shigatoxinas (stec), que comprende al menos un antígeno o una proteína de membrana externa inmunogénica o proteína inmunogénica asociada y conservada en cepas stec.
CN106794141B (zh) 2014-07-16 2021-05-28 诺华股份有限公司 将核酸包封在脂质纳米粒主体中的方法
EP3188760B1 (en) 2014-09-05 2023-12-06 Novartis AG Lipids and lipid compositions for the delivery of active agents
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
ES2811337T3 (es) * 2015-04-07 2021-03-11 Metabolic Explorer Sa Microorganismo modificado para la producción optimizada de 2,4-dihidroxibutirato con eflujo de 2,4- dihidroxibutirato aumentado
US20160317615A1 (en) * 2015-05-01 2016-11-03 Jose Javier Lopez GONZALEZ T cell modulator
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11209972B2 (en) 2015-09-02 2021-12-28 D&M Holdings, Inc. Combined tablet screen drag-and-drop interface
WO2016210384A2 (en) 2015-06-25 2016-12-29 Synlogic, Inc. Bacteria engineered to treat metabolic diseases
HK1255383A1 (zh) 2015-07-31 2019-08-16 The Research Institute At Nationwide Children's Hospital 去除生物膜的肽及抗體
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
EP3365027B1 (en) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu specific antibodies and their use in inhibiting biofilm
JP7016521B2 (ja) * 2015-11-16 2022-02-07 国立大学法人 熊本大学 細胞の再プログラミングを誘導する組成物、及び該組成物を用いた多能性細胞の製造方法
US10568916B2 (en) 2015-11-30 2020-02-25 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
US10086024B2 (en) 2015-11-30 2018-10-02 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
US10933128B2 (en) 2015-11-30 2021-03-02 Joseph E. Kovarik Method and system for protecting honey bees from pesticides
US11529412B2 (en) 2015-11-30 2022-12-20 Seed Health, Inc. Method and system for protecting honey bees from pesticides
US10675347B2 (en) 2015-11-30 2020-06-09 Joseph E. Kovarik Method and system for protecting honey bees from fipronil pesticides
US12239706B2 (en) 2015-11-30 2025-03-04 Seed Health, Inc. Method and system for protecting monarch butterflies from pesticides
WO2017127731A1 (en) * 2016-01-21 2017-07-27 T2 Biosystems, Inc. Nmr methods and systems for the rapid detection of bacteria
EP3701964B1 (en) 2016-02-17 2023-11-08 Pepticom Ltd Peptide agonists and antagonists of tlr4 activation
EP3430168B1 (en) * 2016-03-14 2021-10-20 The Translational Genomics Research Institute Methods and kits to identify klebsiella strains
CN108884483A (zh) * 2016-03-16 2018-11-23 帝斯曼知识产权资产管理有限公司 烟酸核糖苷的微生物生产
EP3450448B1 (en) * 2016-04-27 2021-04-07 Biocells (Beijing) Biotech Co., Ltd. Therapeutic peptide for excitatory neurotoxicity-related injuries
GB201617548D0 (en) * 2016-10-17 2016-11-30 Linnane Pharma Ab Novel biological factor
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11998599B2 (en) 2016-12-30 2024-06-04 Vaxcyte, Inc. Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
EP3565834B1 (en) 2017-01-04 2025-10-22 The Research Institute at Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
AU2018206552C1 (en) 2017-01-04 2025-04-10 Research Institute At Nationwide Children's Hospital DNABII vaccines and antibodies with enhanced activity
WO2018200894A1 (en) 2017-04-28 2018-11-01 Intrexon Corporation Methods and microorganisms for the fermentation of methane to multi-carbon compounds
KR101943081B1 (ko) * 2017-08-31 2019-01-29 (주)케어젠 주름 개선 활성을 나타내는 펩타이드 및 이의 용도
WO2019147743A1 (en) 2018-01-26 2019-08-01 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
SG11202012109UA (en) 2018-07-09 2021-01-28 Codexis Inc Engineered phosphopentomutase variant enzymes
US12150967B2 (en) 2018-08-18 2024-11-26 Seed Health, Inc. Methods and compositions for honey bee health
US12161701B2 (en) 2018-10-05 2024-12-10 Research Institute At Nationwide Children's Hospital Compositions and methods for enzymatic disruption of bacterial biofilms
MX2021003838A (es) 2018-10-05 2021-05-27 Res Inst Nationwide Childrens Hospital Derivados de proteina hmgb1 para la eliminacion de biopeliculas.
KR101991206B1 (ko) * 2018-11-29 2019-06-19 씨제이제일제당 (주) cAMP 수용 단백질 변이체 및 이를 이용한 L-아미노산 제조방법
KR101996767B1 (ko) * 2018-11-29 2019-07-04 씨제이제일제당 (주) cAMP 수용 단백질 변이체 및 이를 이용한 L-아미노산 제조방법
KR101991207B1 (ko) 2018-11-29 2019-06-19 씨제이제일제당 (주) cAMP 수용 단백질 변이체 및 이를 이용한 L-아미노산 제조방법
WO2020117715A1 (en) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment
KR20210101260A (ko) * 2018-12-10 2021-08-18 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 무염색체 동적 활성 시스템
EP3984546A4 (en) * 2019-05-15 2023-09-27 Universidad de Granada GENE THERAPY WITH THE HOKD AND LDRB GENES FOR CANCER TREATMENTS
CA3142272A1 (en) 2019-06-03 2020-12-10 Research Institute At Nationwide Children's Hospital Prebiotic formulations for prevention of sepsis and necroenterocolitis induced neurodevelopmental deficiencies
AU2020297499A1 (en) * 2019-06-21 2022-02-03 Inscripta, Inc. Genome-wide rationally-designed mutations leading to enhanced lysine production in E. coli
CN110441284B (zh) * 2019-07-23 2022-02-15 海南大学 一种可用于痕量检测的表面增强拉曼散射芯片的制备方法及所得产品和应用
KR102183209B1 (ko) * 2019-09-09 2020-11-26 씨제이제일제당 주식회사 L-쓰레오닌 배출 단백질의 변이체 및 이를 이용한 l-쓰레오닌 생산 방법
WO2021085405A1 (ja) * 2019-10-28 2021-05-06 味の素株式会社 ベンズアルデヒドの製造方法
WO2021122528A1 (en) * 2019-12-20 2021-06-24 Basf Se Decreasing toxicity of terpenes and increasing the production potential in micro-organisms
WO2021173808A1 (en) * 2020-02-25 2021-09-02 Synlogic Operating Company, Inc. Recombinant bacteria engineered to treat diseases associated with uric acid and methods of use thereof
CN111778224B (zh) * 2020-07-20 2021-06-01 成都薇合生物科技有限公司 尿酸酶或其同源酶及其应用
CA3191900A1 (en) 2020-08-28 2022-03-03 Codexis, Inc. Engineered amylase variants
IL301857A (en) * 2020-10-07 2023-06-01 Codexis Inc Engineered phosphopentomutase variant enzymes
CN112391331B (zh) * 2020-11-12 2022-09-27 江南大学 一种过表达GatA基因的重组大肠杆菌及其应用
KR102792504B1 (ko) * 2020-12-28 2025-04-09 대상 주식회사 히스티딘에 의한 피드백 억제가 감소된 atp-prt 변이체 및 이를 발현하는 히스티딘 생산 균주
CN114137209B (zh) * 2021-02-01 2024-03-01 中国水产科学研究院黄海水产研究所 一种快速检测牡蛎疱疹病毒抗原的免疫荧光检测试纸条及应用
US11452757B2 (en) * 2021-02-25 2022-09-27 Intron Biotechnology, Inc. Antibacterial composition effective in treating gram negative bacterial infections and method for preparing the same
IL307247A (en) 2021-04-01 2023-11-01 Janssen Pharmaceuticals Inc Production of E. Coli O18 bioconjugates
KR102707457B1 (ko) * 2021-06-11 2024-09-20 씨제이제일제당 주식회사 신규한 MdtH 변이체 및 이를 이용한 O-포스포세린, 시스테인 및 이의 유도체의 생산방법
EP4387596A1 (en) 2021-08-16 2024-06-26 GlaxoSmithKline Biologicals SA Low-dose lyophilized rna vaccines and methods for preparing and using the same
EP4387597A1 (en) 2021-08-16 2024-06-26 GlaxoSmithKline Biologicals SA Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
US20250137050A1 (en) * 2021-08-18 2025-05-01 The Regents Of The University Of California Methods and compositions for determining risk of autism spectrum disorders
CN113897324B (zh) * 2021-10-13 2023-07-28 云南师范大学 一种用作抗锰剂的JcVIPP1重组大肠杆菌及其构建方法
CN114107413B (zh) * 2021-11-03 2023-10-20 江苏香地化学有限公司 一种酶催化胞嘧啶生产胞苷的方法及应用
US11548917B1 (en) * 2021-11-24 2023-01-10 Intron Biotechnology, Inc. Antibacterial composition effective in treating gram negative bacterial infections and method for preparing the same
WO2023122632A1 (en) * 2021-12-21 2023-06-29 Sri International Dual targeting for cell-specific delivery to the central nervous system
CN114522230A (zh) * 2022-01-11 2022-05-24 上海市伤骨科研究所 一种蓝光和对苯醌联合杀菌方法
WO2023139605A1 (en) * 2022-01-20 2023-07-27 Techinvention Lifecare Pvt. Ltd. Lysin polypeptides and compositions thereof against urinary tract infection caused by drug-resistant gram- negative bacteria
CN115286701A (zh) * 2022-03-07 2022-11-04 江苏靶标生物医药研究所有限公司 一种调节哺乳动物的肠道粘膜稳态或炎症性肠病的靶点及其应用
WO2023245129A2 (en) * 2022-06-15 2023-12-21 Quantum-Si Incorporated Directed protein evolution
WO2024073730A2 (en) * 2022-09-29 2024-04-04 The University Of Chicago Methods and systems for rna sequencing and analysis
AU2023362022A1 (en) 2022-10-19 2025-05-01 Glyprovac Aps Glycosylated yghj polypeptides from uropathogenic e. coli
CN118086235A (zh) * 2022-11-28 2024-05-28 宁波酶赛生物工程有限公司 一种合成d-泛解酸的酶催化剂和方法
KR20240120829A (ko) * 2023-01-31 2024-08-08 대상 주식회사 망가니즈 익스포터 신규 변이체 및 이를 이용한 l-히스티딘 생산 방법
GB202303019D0 (en) 2023-03-01 2023-04-12 Glaxosmithkline Biologicals Sa Method of lyophilisation
WO2025017339A1 (en) * 2023-07-14 2025-01-23 Iowa State University Research Foundation, Inc. Escherichia coli nhaa membrane protein drug target and immunogenic compositions therefrom
CN116949027B (zh) * 2023-07-19 2024-12-24 浙江中医药大学 一种尿路致病性大肠埃希菌重组蛋白组合物ls、其构建、表达、纯化方法及其应用
GB202311382D0 (en) 2023-07-25 2023-09-06 Glaxosmithkline Biologicals Sa Lyophilised compostion
WO2025219177A1 (en) 2024-04-18 2025-10-23 Glyprovac Aps Optimized plasmids for expression of yghj polypeptides
CN118388664B (zh) * 2024-05-21 2024-12-03 广东省农业科学院动物卫生研究所 副猪嗜血杆菌融合抗原及其应用
CN119061031A (zh) * 2024-10-08 2024-12-03 安徽农业大学 一种水稻抗除草剂突变基因及其应用

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ241926A (en) 1988-08-25 1993-08-26 Liposome Co Inc Immunisation dosage form comprising a salt of an organic acid derivative of a sterol and an antigen
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
AU651949B2 (en) 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
US5658731A (en) 1990-04-09 1997-08-19 Europaisches Laboratorium Fur Molekularbiologie 2'-O-alkylnucleotides as well as polymers which contain such nucleotides
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
ES2131070T3 (es) 1991-03-01 1999-07-16 Minnesota Mining & Mfg 1h-imidazo(4,5-c)quinolin-4-aminas sustituidas en posicion 1 y sustituidas en posicion 2.
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
AU685443B2 (en) 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
EP0624376B1 (en) 1993-05-13 2000-03-15 American Cyanamid Company Preparation and uses of LOS-depleted outer membrane proteins of gram-negative cocci
EP0708772B1 (en) 1993-07-15 2000-08-23 Minnesota Mining And Manufacturing Company IMIDAZO [4,5-c]PYRIDIN-4-AMINES
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
WO1997004110A1 (en) 1995-07-14 1997-02-06 Somatogen, Inc. Methods for increasing protein expression
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
US6316609B1 (en) * 1996-11-22 2001-11-13 Human Genome Sciences, Inc. Nucleotide sequence of Escherichia coli pathogenicity islands
ATE441432T1 (de) 1997-03-10 2009-09-15 Ottawa Hospital Res Inst Verwendung von nicht-methyliertem cpg dinukleotid in kombination mit aluminium als adjuvantien
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
DE69841807D1 (de) 1997-11-06 2010-09-16 Novartis Vaccines & Diagnostic Neisseriale antigene
ATE352624T1 (de) 1997-11-21 2007-02-15 Serono Genetics Inst Sa Chlamydia pneumoniae genomische sequenzen und polypeptiden, fragmenten und anwendungen davon für nachweis, prevention und heilung
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
DE69941567D1 (de) 1998-01-14 2009-12-03 Novartis Vaccines & Diagnostic Antigene aus neisseria meningitidis
CA2320223A1 (en) 1998-02-12 1999-08-19 American Cyanamid Company Pneumococcal and meningococcal vaccines formulated with interleukin-12
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
KR20010042573A (ko) 1998-04-09 2001-05-25 장 스테판느 애쥬번트 조성물
DE69937419T2 (de) 1998-05-01 2008-07-24 Novartis Vaccines and Diagnostics, Inc., Emeryville Neisseria Meningitidis Antigene und Zusammenstellungen
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
DE69924262T3 (de) 1998-08-14 2009-07-23 Novartis Vaccines and Diagnostics, Inc., Emeryville Verfahren zur herstellung von durch hefe exprimierte hpv typs 6 und 16 kapsid-proteinen
CN101926993B (zh) 1998-10-16 2013-12-04 史密丝克莱恩比彻姆生物有限公司 佐剂系统及疫苗
WO2000027994A2 (en) 1998-11-12 2000-05-18 The Regents Of The University Of California Chlamydia pneumoniae genome sequence
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
WO2000056359A2 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Vaccine against streptococcus pneumoniae
DE60039198D1 (de) 1999-03-26 2008-07-24 Vical Inc Adjuvanszusammensetzungen zur Erhöhung der Immunantwort bezüglich Polynukleotid-basierenden Impfstoffen
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
BR0010361A (pt) 1999-04-30 2003-06-10 Chiron Corp Seq ências genÈmicas de neisseria e uso destas
WO2000068253A1 (en) 1999-05-05 2000-11-16 Sterrenbeld Biotechnologie North America, Inc. Dna promoter sequence for gene expression
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
WO2001021207A2 (en) 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
TR200200777T2 (tr) 1999-09-24 2002-09-23 Smithkline Beecham Biologicals S.A. Polioksietilen alkil eteri veya esteriyle en az bir iyonik olmayan yüzey aktif maddeli adjuvant.
EP1311288A1 (en) 2000-01-20 2003-05-21 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
PT1790660E (pt) 2000-02-28 2012-09-17 Novartis Vaccines & Diagnostic Expressão heteróloga de proteínas de neisseria
AU2001277840A1 (en) 2000-03-07 2002-03-04 Hyseq, Inc. Novel nucleic acids and polypeptides
EP1328641A2 (en) * 2000-03-10 2003-07-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polynucleotides isolated from e. coli of nature b2/d+ a-, and uses thereof
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
WO2002002606A2 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
ATE448226T1 (de) 2000-09-01 2009-11-15 Novartis Vaccines & Diagnostic Aza heterocyclische derivate und ihre therapeutische verwendung
KR100732206B1 (ko) 2000-09-11 2007-06-27 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 티로신 키나제 억제제로서의 퀴놀리논 유도체
CA2423487C (en) 2000-09-26 2015-12-15 Hybridon, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
WO2002059320A2 (en) * 2000-10-19 2002-08-01 Wisconsin Alumni Research Foundation Dna sequences of escherichia coli cft073
AU1412702A (en) 2000-10-27 2002-05-06 Chiron Spa Nucleic acids and proteins from streptococcus groups a and b
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
UA75622C2 (en) 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
ATE489968T1 (de) 2001-03-09 2010-12-15 Id Biomedical Corp Quebec Proteosom-liposaccharid-vakzine-adjuvans
WO2002077183A2 (en) * 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
WO2002091998A2 (en) 2001-05-11 2002-11-21 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
EP1409013B1 (en) 2001-07-26 2009-11-18 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising aluminium adjuvants and histidine
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
CA2492826C (en) 2001-09-14 2016-12-13 Cytos Biotechnology Ag Encapsulation of unmethylated cpg-containing oligonucleotides into virus-like particles: method of preparation and use
JP4360906B2 (ja) 2001-09-14 2009-11-11 サイトス バイオテクノロジー アーゲー ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
BR0214407A (pt) 2001-11-27 2004-10-19 Anadys Pharmaceuticals Inc Compostos, composições farmacêuticas e método de modulação das imunoatividades da citocina
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US20030165870A1 (en) 2002-03-01 2003-09-04 Blattner Frederick R. Novel sequences of E. coli CFT073
EP1342784A1 (en) 2002-03-06 2003-09-10 Mutabilis S.A. ExPEC-specific proteins, genes encoding them and uses thereof
DK1499311T3 (da) 2002-03-29 2010-03-08 Novartis Vaccines & Diagnostic Substituerede benzaboler og anvendelse deraf som RAF-kinaseinhibitorer
EP1511746A2 (en) 2002-05-29 2005-03-09 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
FR2842210B1 (fr) * 2002-07-09 2012-12-14 Mutabilis Determinants de pathogenicite utilisables comme cibles pour l'elaboration de moyens de prevention et de controle d'infections bacteriennes et/ou de la dissemination systemique
EP1537099B1 (en) 2002-08-23 2010-08-11 Novartis Vaccines and Diagnostics, Inc. Pyrrole based inhibitors of glycogen synthase kinase 3
SI2353608T1 (sl) 2002-10-11 2020-12-31 Glaxosmithkline Biologicals Sa Polipeptidna cepiva za široko zaščito proti hipervirulentnim meningokoknim linijam
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
US20040209370A1 (en) 2002-12-19 2004-10-21 Wonchul Suh Method for chromosomal engineering
AU2003300021A1 (en) 2002-12-27 2004-07-29 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
ES2391770T3 (es) 2003-01-21 2012-11-29 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos de triptantrina para la potenciación inmune
GB0301554D0 (en) 2003-01-23 2003-02-26 Molecularnature Ltd Immunostimulatory compositions
EP1441036A1 (en) 2003-01-27 2004-07-28 Université de Nantes Method for the identification and isolation of strong bacterial promoters
EP2258365B1 (en) 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
CN1812809A (zh) 2003-06-26 2006-08-02 希龙公司 用于沙眼衣原体的免疫原性组合物
JP4049045B2 (ja) 2003-07-28 2008-02-20 トヨタ自動車株式会社 蓄熱装置付きエンジンシステム
EP1721283B1 (en) * 2004-02-06 2022-11-30 Council of Scientific and Industrial Research Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential
CA2557353A1 (en) 2004-03-02 2005-09-15 Chiron Corporation Immunogenic compositions for chlamydia pneunomiae
SI2351772T1 (sl) 2005-02-18 2016-11-30 Glaxosmithkline Biologicals Sa Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso

Also Published As

Publication number Publication date
HUE030881T2 (en) 2017-06-28
PL1858920T3 (pl) 2016-12-30
DK1858920T3 (en) 2016-02-29
SI1858920T1 (sl) 2016-07-29
US20160244489A1 (en) 2016-08-25
JP2008529558A (ja) 2008-08-07
SI2351772T1 (sl) 2016-11-30
US10035826B2 (en) 2018-07-31
CY1117732T1 (el) 2017-05-17
HUE027400T2 (en) 2016-10-28
WO2006089264A3 (en) 2007-04-05
WO2006089264A2 (en) 2006-08-24
NZ597769A (en) 2013-09-27
SG160329A1 (en) 2010-04-29
EP1858920B1 (en) 2016-02-03
US9334313B2 (en) 2016-05-10
CA2601924A1 (en) 2006-08-24
US8758764B2 (en) 2014-06-24
LT2351772T (lt) 2016-10-10
JP2012152228A (ja) 2012-08-16
MX2007010043A (en) 2008-08-29
EP1858920A2 (en) 2007-11-28
NZ561042A (en) 2011-03-31
ES2595363T3 (es) 2016-12-29
US20140356389A1 (en) 2014-12-04
AU2006214064B2 (en) 2012-04-26
US20180298064A1 (en) 2018-10-18
NZ597685A (en) 2013-12-20
AU2006214064A1 (en) 2006-08-24
EP2351772A1 (en) 2011-08-03
IL206012A0 (en) 2010-11-30
US20080193470A1 (en) 2008-08-14
WO2006089264A8 (en) 2008-03-06
PL2351772T3 (pl) 2017-01-31
CY1118149T1 (el) 2017-06-28
DK2351772T3 (en) 2016-09-05
EP2351772B1 (en) 2016-07-13
PT2351772T (pt) 2016-09-22
ES2569654T3 (es) 2016-05-12
IL185359A0 (en) 2008-02-09

Similar Documents

Publication Publication Date Title
IL185359A0 (en) Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
IL185547A0 (en) Lipocalin protein
EP1856291A4 (en) NUCLEIC ACIDS AND PROTEINS, AND METHODS OF MAKING AND USING SAME
IL188611A (en) Type 1sp polypeptides are altered at the n-terminal end and used
EP2061884A4 (en) SENSOR PROTEINS AND TEST PROCEDURES THEREFOR
EP1725661A4 (en) POLYNUCLEOTIDE FOR THE DETECTION OF SCHERICHIA COLI O157
GB0507537D0 (en) Protein resistant surfaces
IL193699A0 (en) Proteins, nucleic acids and medicaments
EP1904845A4 (en) IMPROVED RESULTS AND APPLICATION OF COMPARISON EXAMPLES OF PROTEIN EXPRESSIONS
SG131104A1 (en) Protein microarray slide
EP1666588A4 (en) NOVEL TRANSPORTED PROTEIN
IL173764A0 (en) Amino acids with affinity for the alpha2delta-protein
GB0514482D0 (en) Protein
HK1111175A (en) Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
GB0724832D0 (en) Proteins and nucleic acids
EP1925670A4 (en) HIGH EXPRESSION ESCHERICHIA COLI VECTOR AND USES THEREOF
EP1759000A4 (en) POLYNUCLEOTIDES FOR DETECTION OF ESCHERICHIA COLI
GB0511861D0 (en) Proteins
GB0522113D0 (en) vWFA-domain containing proteins
GB0514481D0 (en) Proteins
GB0514788D0 (en) Proteins
GB0518460D0 (en) Protein assay
GB0508160D0 (en) Protein
GB0514718D0 (en) Protein
GB0514717D0 (en) Protein

Legal Events

Date Code Title Description
FG Grant or registration